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1 |  BACKGROUND
The incidence of prostate cancer has increased in most 
European countries, whereas prostate cancer mortality rates 
have declined.1,2 Most Western European countries have ex-
perienced a sharp rise in the incidence of prostate cancer. 
The observed trend change in the incidence and mortality of 
prostate cancer may be partly related to opportunistic pros-
tate-specific antigen (PSA) screening and advances in pros-
tate cancer treatment and diagnostic procedures.3 However, 
this progress is usually accompanied by a high risk of overdi-
agnosis. Various studies indicated that opportunistic PSA 
testing is less efficient and associated with a higher risk 
of overdiagnosis compared to organized screening.4,5 An 
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Abstract
Background: Prostate cancer screening incurs a high risk of overdiagnosis and over-
treatment. An organized and age-targeted screening strategy may reduce the associ-
ated harms while retaining or enhancing the benefits.
Methods: Using a micro-simulation analysis (MISCAN) model, we assessed the 
harms, benefits, and cost-effectiveness of 230 prostate-specific antigen (PSA) screen-
ing strategies in a Dutch population. Screening strategies were varied by screening 
start age (50, 51, 52, 53, 54, and 55), stop age (51-69), and intervals (1, 2, 3, 4, 8, 
and single test). Costs and effects of each screening strategy were compared with a 
no-screening scenario.
Results: The most optimum strategy would be screening with 3-year intervals at 
ages 55–64 resulting in an incremental cost-effectiveness ratio (ICER) of €19 733 
per QALY. This strategy predicted a 27% prostate cancer mortality reduction and 28 
life years gained (LYG) per 1000 men; 36% of screen-detected men were overdiag-
nosed. Sensitivity analyses did not substantially alter the optimal screening strategy.
Conclusions: PSA screening beyond age 64 is not cost-effective and associated with 
a higher risk of overdiagnosis. Similarly, starting screening before age 55 is not a 
favored strategy based on our cost-effectiveness analysis.
K E Y W O R D S
harms and benefits; cost-effectiveness, micro-simulation, prostate cancer, prostate-specific antigen 
(PSA) screening
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organized and age-targeted screening strategy may reduce the 
associated harms while retaining or enhancing the benefits.
While screening for prostate cancer remains controversial, 
various large-scale studies have confirmed the benefit of PSA 
screening.6-8 Similarly a secondary analysis confirmed that the 
Prostate, Lung, Colorectal and Ovarian screening Trial (PLCO) 
and European Randomized Study of Screening for Prostate Cancer 
(ERSPC) provide a compelling and consistent evidence that screen-
ing reduces prostate cancer mortality.9 However, the question as 
to the age at which PSA screening should start and especially at 
what age it should stop remains debatable, mainly because of the 
associated harms and costs. Finding the optimal screening strat-
egy can lead to a better balance between the harms and benefits 
for citizens. Recently, the European Association of Urology (EAU) 
recommended that a baseline PSA test should be offered to men 
aged >50 and, men >45 years of age having a family history of 
prostate cancer or men of African-American origin,10 whereas the 
US Preventive Services Task Force (USPSTF) recommended age 
55 as the starting age and that the decision to undergo periodic PSA-
based screening for prostate cancer should be an individual one.11
Even though evidence for the benefit of prostate can-
cer screening under age 55 seems less conclusive, there are 
some studies that suggest a benefit of screening between ages 
50 and 54. Recently, the 18-year follow-up study from the 
Goteborg randomized control trial, one center of the ERSPC 
trial, showed a large and statistically significant relative pros-
tate cancer mortality reduction (RR = 0.31) for the attendees 
in this age group.8 Similarly, two other recent studies indi-
cated a possible benefit of screening for this age group.12,13 
Although the overall result reported from the CAP (Cluster 
Randomized Trial of PSA Testing for Prostate Cancer) trial 
was insignificant, the highest prostate cancer mortality re-
duction was seen in this age group.13 The insignificant result 
from the CAP trial may be related to the single screening 
offered and its lower acceptance rate (36%).14
Although multiple studies on prostate cancer screening 
have been conducted, they have mainly focused on screening 
starting at age 556,7,15,16 or did not calculate life years gained or 
quality-adjusted life years (QALYs) gained.17-19 Furthermore, 
finding an optimum screening strategy requires comparison 
of several screening strategies. The present study aimed to as-
sess the harms, benefits, and an optimum cost-effectiveness 
scenario of prostate cancer screening for men from age 50 on-
wards in a Dutch population. A total of 230 screening strate-
gies were evaluated using a micro-simulation analysis model.
2 |  MATERIALS AND METHODS
2.1 | Model description
For this study we used a micro-simulation screening anal-
ysis (MISCAN) model in order to assess the effects of 
prostate cancer screening. MISCAN prostate model has 
been described extensively before.6,20 In short it is a sto-
chastic model that simulates individual life histories of men 
and the natural life histories of prostate cancer. Overall, the 
model consists of 18 preclinical detectable states combined 
with three stages (T1, T2, and T3), three Gleason scores (7, 
<7, and >7) and two metastatic states (local-regional and 
distant). Each individual in the simulation starts with no 
prostate cancer. Once the individual has prostate cancer, the 
cancer can progress to different screen-detectable preclini-
cal states. From each preclinical state, the cancer has a prob-
ability to progress to clinical prostate cancer (detected by 
symptoms) (Figure 1).
In the model, prostate cancer incidence and mortality are 
first simulated in the absence of screening. Prostate cancer 
survival in the absence of treatment (baseline survival) was 
estimated at clinical detection based on surveillance, epide-
miology, and end results data from the pre-PSA era (1983-
1986). Those clinically detected men with local disease and 
having received primary treatment (radical prostatectomy or 
radiation therapy) have improved survival rates with a haz-
ard ratio of 0.56 compared to baseline survival.21 For distant 
cases it is assumed that treatment has no effect on survival. 
Following this, the effect of PSA screening on the natural 
history of prostate cancer is simulated. In our model, the 
effect of PSA screening on prostate cancer mortality is de-
pendent on the lead time using a lead time-dependent cure 
probability.22
In our model, the allocation of treatments (radical prosta-
tectomy, radiation therapy, and active surveillance) after the 
diagnosis of prostate cancer was based on age, stage, and 
Gleason score as described in previous studies.3,22 It was 
assumed that 30% of men switch from active surveillance 
to secondary treatment during the first 7  years.6 A Dutch 
life table was applied to model nonprostate cancer-related 
death.23
2.2 | Model calibration
The MISCAN prostate model was previously calibrated to 
ERSPC data by estimating parameters on duration, sensi-
tivity, and lead time–dependent cure probability.15 In order 
to adapt the model to the Dutch situation and also account 
for younger age groups (50-54), the model was calibrated 
to prostate cancer incidence among the Dutch population 
between 1989 and 2013 by 5-year age categories from age 
50 to 75.24 Furthermore, prostate cancer mortality predicted 
by the model was compared with observed prostate cancer 
mortality (among the Dutch population) over the same pe-
riod (1989-2013) to validate our model. More information 
on the calibration of the model is available in the supple-
mentary part of this manuscript. Additional descriptions 
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about the four components of MISCAN prostate model (de-
mography, natural history, screening, and treatment) can be 
found at https://cisnet.flexkb.net/mp/pub/CISNET_Model 
Profi le_PROST ATE_ERASM US_001_12152 009_69754.
pdf.
2.3 | Screening strategies
A hypothetical cohort of 10 million men in the Netherlands 
aged 50 in 2020 was sampled and simulated over a lifetime 
period. The reason why we used a larger sample size than the 
male population in the Netherlands is to avoid a stochastic 
noise in the model. This number was selected by increasing 
the sample size until the model outputs get stable. Screening 
strategies were varied by screening start age, stop age, and 
screening intervals. The screening start age varied between 
50 and 55 years, and the age at which screening was stopped 
varied between the screening start ages and age 69. Screening 
intervals of 1, 2, 3, 4, and 8  years and once-in-a-lifetime 
screenings were applied.
In our study the biopsy compliance rate after a positive 
screen test result was assumed to be 90%, with a sensitiv-
ity of 90% as observed in the ERSPC Rotterdam data.25,26 
Most ERSPC centers used a PSA cutoff value of 3 ng/mL 
as an indication for biopsy,27 and a similar cutoff was used 
in our model. A screening attendance of 80% was assumed. 
For each strategy a total number of invitations, PSA tests 
done, prostate cancer detected (with and without screening), 
overdiagnosed cancer, prostate cancer death (with and with-
out screening), and life years gained were predicted. The 
total number of biopsies was estimated by using the number 
of screen-detected cancers and a mean positive predictive 
value of 22.7% of a biopsy in the screen arm of the ERSPC26 
and by using the number of clinically detected cancers and 
the positive predictive value of 35.8% of a biopsy in the con-
trol arm.28
For each screening strategy, overdiagnosis was estimated 
as a proportion of screen-detected prostate cancers (ie, overdi-
agnosed prostate cancers divide by screen-detected prostate 
cancers). The screen-detected prostate cancers composed of 
both overdiagnosed prostate cancers and relevant (nonoverdi-
agnosed) prostate cancers. The term overdiagnosis was de-
fined as the detection of a prostate cancer during screening 
that would not have been clinically diagnosed during the 
man's lifetime in the absence of screening. All the outcomes 
(costs and effects) were estimated over a lifetime period and 
presented per 1000 men.
2.4 | Quality of life, costs, and cost-
effectiveness
All utility estimates, unit costs (costs of screening, biopsy, 
primary treatment, follow-up and palliative care for advanced 
cases), and durations in screening, biopsy, and treatment 
phases were obtained from a previous study6 (Table S1). 
Our analysis did not consider indirect costs. As described in 
a previous study,15 the utility estimates for the postrecovery 
period was obtained by combining the percentage of men 
with side effects from treatment with the utility estimates for 
those side effects. This resulted in utility estimates of 0.95 for 
all men during the period of 1-10 years after diagnosis and 
after receiving radical prostatectomy or radiation therapy. 
F I G U R E  1  The MISCAN prostate 
cancer model. The model also contains 
a distinction between local and distant 
stages, but for the sake of simplicity it is not 
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The utility estimates range between 0 (death) and 1 (perfect 
health) and one minus the utility estimate gives a loss in util-
ity at each health state. The total loss in quality of life was 
estimated as follows:
where u, d, and n represent the utility estimate, duration 
(in years, eg 2 months = 1/6 year), and number of men in 
each health state (i), respectively. The utility estimates and 
durations are presented in Table S1. The number of men in 
each health state was based on the model prediction. The let-
ter “k” indicates the total number of health states.
QALYs gained were calculated by subtracting the total 
loss in quality of life from the net life years gained as a result 
of screening.
After determining the costs and effects of each screening 
strategy, the results were compared with a no-screening sce-
nario. Both strategies that were at least as expensive as and 
less effective (also called “strongly dominated strategies”) 
than an alternative option and weakly dominated strate-
gies were excluded from the cost-effectiveness analyses. A 
weakly dominated strategy is defined as a strategy whose 
incremental cost-effectiveness ratio (ICER) is greater than 
that of a more effective strategy.29 The remaining strategies 
were regarded as efficient strategies and listed from lowest 
to highest according to their ICER. The ICER was calcu-
lated as the additional costs divided by additional QALYs 
gained compared with the previous less expensive strategy. 
The optimum efficient strategy was identified by compar-
ing the ICERs with the willingness-to-pay (WTP) threshold 
per QALY. Considering a commonly used WTP threshold 
of €20 000 in a Dutch situation,30 a strategy (among effi-
cient strategies) with the highest ICER below this threshold 
was taken as the optimum strategy. All costs and effects 
were estimated at a discount rate of 3.5% and presented in 
comparison with the no-screen scenario, unless otherwise 
stated.
2.5 | Sensitivity analysis
Univariate sensitivity analyses were conducted to test the 
robustness of the model results under different assumptions. 
Utility estimates of different health states and costs of screen-
ing, diagnosis, and treatment were the selected parameters 
for these analyses. The utility estimates in each health state 
(except for the terminal illness and palliative therapy) were 
varied using the highest (favorable) and lowest (unfavorable) 
value (Table S1). For the terminal illness and palliative ther-
apy, it is favorable for screening when the utility is low.15 All 
costs were varied by ±20%.
3 |  RESULTS
3.1 | Calibration and validation
Our model adequately predicted the prostate cancer incidence 
trends in the Netherlands between 1989 and 2013 (Figure 
S1). Furthermore, the model reasonably predicted the pros-
tate cancer mortality in the Netherlands (except for the 70-74 
age group) over the same time period (1989-2013), and this 
was taken as validation of the model (Figure S2).
3.2 | Effects of various screening strategies
For single screening strategies (once only), screening at age 
57 was found to be most efficient which resulted in a 9.5 life 
years gain and 8.2% prostate cancer mortality reduction, with 
31% of screen-detected cancer overdiagnosed. Screening at 
4-year interval from age 55 to 59 (2 tests) and at 3-year inter-
val from age 55 to 61 (3 tests) were found to be other efficient 
strategies with ICER below the optimum cost-effectiveness 
cutoff (Table 1). Screening at 3-year intervals from age 55 
to 64 (4 tests) was regarded as the optimum screening strat-
egy with an ICER closest to the optimum cost-effectiveness 
cutoff. Biennial screening between 51 and 69 (9 tests) and 
annual screening between age 50 and 69 (20 tests) were ac-
companied by a maximum life years gain of 41 and 47 years 
per 1000 men with a 42% and 47% life time prostate cancer 
mortality reduction, respectively. However, these benefits 
were accompanied by a higher risk of overdiagnosis (39% 
and 41%, respectively) (Table 1) and higher net costs for the 
corresponding life years or QALYs gained (Figure S3, and 
Figure 2) compared to other strategies. The fewest life years 
were gained with a single screening at age 50. In a one-time 
screening strategy, the highest QALYs were attained at age 
62. For all screening intervals used in our study, screening 
between an age group 50 and 54 generally yielded a lower 
number life years gain and prostate cancer mortality reduc-
tion than screening in age groups 55-59 or 55-64. The harms, 
benefits, and total net costs for each screening strategy are 
presented in the appendix (Table S2).
3.3 | Cost-effectiveness
The total costs of prostate cancer screening, diagnosis, and 
treatment ranged from €739 561 at no screening to €1 583 786 
with annual screening of age 50-69 per 1000 men (3.5% dis-
counted). The ICER of efficient strategies, strategies on the 
efficient frontier, increased from €10  211 per QALY (sin-
gle test at age 56) to €97 784 per QALY (annual screening 
between ages 50 and 69). As indicated in Table 1, most of 
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less, and screening strategies beyond age 64 were found to be 
less cost-effective and associated with higher probabilities of 
overdiagnosis. Screening at 3-year intervals from ages 55 to 
64 resulted in an ICER of €19 733 per QALY, which is closest 
to the WTP threshold of €20 000 per QALY, and regarded as 
the optimum strategy. A 27% prostate cancer mortality re-
duction and 28 life years gained per 1000 men were predi-
cated in association with this strategy. Of all screen-detected 






Overdiagnosis, as % of screen-
detected men
ICER in € Per 
QALY
56 single test 1 - 6.9 29.3 10 211
57 single test 1 - 8.2 30.7 10 946
55-58 2 3 12.2 31.4 12 814
55-59 2 4 13.8 31.6 13 129
55-61 3 3 19.8 34.6 14 738
54-63 4 3 25.1 34.7 18 417
55-64 4 3 27.2 35.8 19 733
54-64 6 2 30 34.9 22 395
55-65 6 2 32.2 36 24 589
53-65 7 2 33 35.6 24 819
54-66 7 2 35 36.7 28 053
53-67 8 2 37.6 37.4 29 565
52-68 9 2 39 38.1 36 805
50-68 10 2 40.3 37.9 43 831
51-69 10 2 42 38.9 50 572
53-69 17 1 46 38 55 083
52-69 18 1 46.4 37.9 57 448
50-69 20 1 46.9 41.3 97 784
Abbreviations: ICER, incremental cost-effectiveness ratio; PCM, prostate cancer mortality; QALY, quality-adjusted life years.
F I G U R E  2  Net costs and QALYs gained per 1000 men. The start and end age of most optimal strategies given 1, 2, 3, 4, 8, and once depicted 
in the figure. Numbers in the legend indicate the screening intervals used in the model. Eff frontier, efficient frontier







Base case 55-64 3 19 733
Highest utility for screening attendance 54-63 3 17 960
Lowest utility for screening attendance 55-64 3 19 416
Highest utility for diagnostic phase 55-64 3 19 371
Lowest utility for diagnostic phase 54-63 3 18 582
Highest utility for diagnosis 55-64 3 19 615
Lowest utility for diagnosis 55-64 3 19 853
Highest utility at 2 mo after RP treatment 55-64 3 19 284
Lowest utility at 2 mo after RP treatment 55-64 3 19 956
Highest utility at 2 mo after RT treatment 55-64 3 19 516
Lowest utility at 2 mo after RT treatment 55-64 3 19 771
Highest utility at 2 mo to 1 y after RP treatment 55-64 3 18 427
Lowest utility at 2 mo to 1 y after RP treatment 54-63 3 19 427
Highest utility at 2 mo to 1 y after RT treatment 55-64 3 18 835
Lowest utility at 2 mo to 1 y after RT treatment 54-63 3 19 494
Highest utility for AS 55-64 3 17 630
Lowest utility for AS 55-61 3 19 217
Highest utility for postrecovery period 55-65 2 19 150
Lowest utility for postrecovery period 55-61 3 15 816
Highest utility for Palliative therapy 55-61 3 17 085
Lowest utility for Palliative therapy 55-67 2 18 133
Highest utility for terminal illness 54-63 3 18 732
Lowest utility for terminal illness 55-64 3 19 380
Costs of PSA test +20% 54-63 3 18 710
Costs of PSA test −20% 55-63 2 19 472
Costs of invitation +20% 55-64 3 19 673
Costs of invitation −20% 55-64 3 19 794
Costs of biopsy +20% 54-63 3 18 664
Costs of biopsy −20% 55-64 3 19 343
Costs of RP +20% 55-64 3 19 562
Costs of RP −20% 55-64 3 17 697
Costs of RT +20% 54-63 3 19 986
Costs of RT −20% 55-64 3 17 429
Costs of AS +20% 54-63 3 18 710
Costs of AS −20% 55-64 3 19 267
Costs of staging +20% 55-64 3 19 815
Costs of staging −20% 55-64 3 19 651
Costs of follow-up +20% 55-64 3 19 783
Costs of follow-up −20% 55-64 3 19 683
Costs of advanced case +20% 55-64 3 18 940
Costs of advanced case −20% 54-63 3 18 989
Abbreviations: AS, active surveillance, ICER, incremental cost-effectiveness ratio, RP, radical prostatectomy; 
RT, radiation therapy.
T A B L E  2  Optimal strategies in 
base case and under a variety of different 
assumptions with their incremental cost-
effectiveness ratio
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men using this strategy, 36% were overdiagnosed. Extending 
the screening start age before age 55 (age 50 at the earliest) is 
less desirable (Table 1).
3.4 | Sensitivity analyses
The results from the sensitivity analyses showed that for 77% 
of the analyses, screening from ages 55 to 64 with 3-year 
screening intervals remained an optimal strategy, as in the 
base case scenario. Varying the utility estimate of the postre-
covery period produced the greatest effect on screening stop 
age, screening frequency, and incremental cost-effectiveness 
ratio of the optimum strategy. Using an unfavorable utility 
estimate for this parameter shifted the screening stop age of 
the optimum strategy from 64 to 61 (compared with the base 
case) with an ICER of €15 816. When the highest utility esti-
mate was assumed for the same parameter, the screening stop 
age increased from 64 to 65, the screening frequency went 
from 3 to 2, QALYs gained rose from 24 to 33 (with a pro-
portionate increase in the probability of overdiagnosis), and 
the ICER fell by 30%. A ±20% variation in unit costs caused 
the ICER of the optimum strategy to vary between €17 429 
and €19 986 and also proportionately increased the effect of 
changing treatment costs (Table 2).
4 |  DISCUSSION
According to the model predictions, the highest QALYs were 
estimated for age 62 in a one-time screening strategy; ex-
tending once only screening to age 69 resulted in a loss in 
QALYs. However, extending the screening stop age yielded 
additional QALYs for the other strategies (Figure  2). This 
study shows that screening strategies with intervals of 4 years 
or shorter were more efficient than strategies with longer in-
tervals. With 3-year intervals, screening between ages 55 and 
64 was found to be the optimum strategy. Screening beyond 
age 64 is less cost-effective and associated with a higher risk 
of overdiagnosis.
When comparing screening between age group 50 and 54 
and age groups 55 and 59 or 55 and 64, the former resulted 
in lower life years and QALYs gain, and lower prostate can-
cer mortality reduction than the other two age groups. The 
difference in prostate cancer mortality benefit between these 
strategies may be due to the lower chance of lethal prostate 
cancer among younger age groups.
An earlier study with our model showed an increasing 
trend in QALYs gained only up to age 63. QALYs started 
to fall when screening stop age extended beyond this age.6 
A possible explanation for these contradictory results could 
be more effectiveness, and the lower overdiagnosis pre-
dicted in this study using the updated model compared to 
the previous one, because treating overdiagnosed cancer is 
the main cause of QALY loss. Updates in the model inputs 
(hazard of clinical prostate cancer detection and/or hazards 
of onset of a preclinical prostate tumor) in the current study 
could be the reason for the different overdiagnosis projec-
tions in the present and earlier study.6 On the other hand 
our findings are consistent with the earlier study with our 
model that screening is less cost-effective at higher age and 
with longer screening intervals. When the optimum strategy 
in the current study was compared with that in the previous 
study (age group 55-59 with 2-year intervals), it resulted in 
10 more life years gained at a much lower ICER and a 3% 
higher probability of overdiagnosis.6 The 27% prostate can-
cer mortality reduction estimated for the optimum strategy 
in the present study is in the same order as the 30% breast 
cancer mortality reduction reported in population-based 
breast cancer screening, which is already established in the 
Netherlands.31
Generally, much lower net costs of screening and higher 
QALYs were predicted in the present study (Figure 2) as com-
pared with some previous cost-effectiveness studies.6,32,33 
Factors that could explain this difference include differences 
in background risk (incidence), model assumptions, and pro-
portions of cases assigned in each treatment category (radical 
prostatectomy, radiation therapy, and active surveillance). 
The higher QALYs gained reported in our study is in line 
with two previous studies.15,34
Most of the results in our study are robust for the univari-
ate sensitivity analyses. However, there are some parameters 
that produced a considerable effect on quality of life, which 
in turn altered the optimum strategy. Among these, the utility 
of postrecovery treatment is the principal one. This is due to 
the longer duration (9 years in our study) of this health state 
compared to the other health states. The use of a favorable 
utility estimate for this health state increased the QALYs gain 
by 8 at a lower ICER, whereas an unfavorable utility reduced 
the QALYs gain by 6 compared to the base case scenario. 
Men undergoing prostatectomy or radiation therapy for lo-
calized prostate cancer experience a decline in all functional 
outcomes (urinary, sexual, and bowel functions) throughout 
early, intermediate, and long-term follow-up.35
To our knowledge, the present study is the first that as-
sesses the harms, benefits, and cost-effectiveness of prostate 
cancer screening using Dutch population data. In addi-
tion, the existing studies, none of which are specific to the 
Netherlands, mainly focused on screening starting at age 
55.6,7,15,16 Therefore, the main strength of our study is that 
we were capable of considering screening before age 55, 
unlike several previous studies that mentioned this point as 
one of their study limitations.6,15,16 Another strength of this 
study is that we evaluated 230 screening scenarios, and find 
possible to recommend strategies when choosing for 1, 2, 3, 
or 4 tests.
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Our study also had some limitations. Firstly, we did not 
use risk-stratified screening. Several studies suggest risk-
based screening (for instance, screening based on PSA 
level) as one method to reduce overdiagnosis.36,37 Similarly, 
various studies suggest that a magnetic resonance imaging 
(MRI)-guided biopsy could minimize the risk of overdi-
agnosis,38-40 but MRI is not included in our screening pro-
tocol. We did not consider indirect costs in our analysis. 
Therefore, the actual total costs of prostate cancer screen-
ing may turn out to be higher than estimated in our study. 
Finally, our results are from a population-based screening, 
and this may not be directly applicable in clinical prac-
tice under certain conditions. For instance, a man with 
high risk of prostate cancer may benefit from screening/
rescreening beyond the screening stop age recommended 
in our study. Further studies that include selection of men 
based on their risk, such as using baseline PSA, comor-
bidity status, or using nomograms and/or MRI, as triage 
test may allow to screen older age groups with a minimal 
harm, or may improve the cost-effectiveness.
In conclusion, our results indicate that PSA screening be-
yond age 64 is not cost-effective and associated with a higher 
risk of overdiagnosis. Likewise, starting screening before age 
55 is not a favored strategy based on our cost-effectiveness 
analysis. Screening men with 4 tests maximum, from ages 55 
to 64 with 3-year intervals is considered the optimum screen-
ing strategy at a WTP threshold of €20 000.
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